Alcobra: status of metoclopramine orphan drug granted by FDA for fragile X syndrome

December 18, 2013 source: alcobra Co., Ltd is a new biopharmaceutical company, which is committed to the development and commercialization of mg01ci or metadoxin, a patent candidate drug for the treatment of cognitive impairment On Wednesday, the company announced that the U.S Food and drug administration has approved the award of "orphan drug" to metadoxin, a drug used to treat fragile X syndrome "We have recently obtained positive results in the preclinical study of fragile X and believe that this result supports the research clinical trial to be launched in 2014 Recently, we have raised about 38 million US dollars through the secondary issuance of securities, and we believe that there is enough money to find companies that plan to submit new drug applications or supplement new drug applications for mg01ci or metoprolactin for adult ADHD, pediatric ADHD and mg01ci or metoprolactin, "said Dr alcobra, President and CEO of alcobra In September, alcobra announced the positive results of preclinical studies of fragile X syndrome In this study, the effective animal model of fragile X syndrome (FMR1 knockout mouse model) was used to show that mg01ci significantly improved cognitive and social functions Fragile X syndrome or FXS is a genetic disease that can lead to intellectual disability, behavioral and learning challenges and a variety of physical characteristics Behavioral characteristics include hyperactivity, autism and autism behavior, social anxiety, stereotyping, minimal eye contact, sensory impairment, and increased risk of attack Fragile X syndrome is the main known genetic cause of autism, accounting for about 2-5% of autism cases Original link: http://